+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Hematological Malignancies Market: By Treatment, & By Region - Forecast 2016-2021

  • ID: 3920053
  • Report
  • 153 pages
  • IndustryARC
1 of 2
Hematological malignancies or blood cancers are a derivative of cells of blood forming tissue. Blood cancer can start in the bone marrow and thereby affect the blood production its functionality. Stem cells in the bone marrow help developing namely three types of blood cells: red blood cells, white blood cells and platelets. During hematological malignancies, there is an uncontrolled growth of abnormal blood cells which are unable to prevent infections caused to our body. These may include leukaemia, lymphoma and myeloma. The market is segmented on the basis of mode of treatment available. Globally, the growth is driven by rising prevalence of diseases and research practices focusing on effective drugs and formulations in the market. Further, it is estimated that number of drugs are under development due to these research practices. These drugs include histone deacetylase (HDAC) inhibitors, immunomodulatory drugs and proteasome inhibitors and are expected to enter in the market during forecast period. These drivers are coupled with other factors such as, increasing medical infrastructure and rising awareness about the diseases are also estimated to contribute towards the market growth. High cost of the diagnosis and treatment is a major restraint for the market.

This report identifies the global Hematological Malignancies market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Hematological Malignancies market.

Geographically North America dominates the global Hematological Malignancies market, and is projected to have fastest growth, owing to higher number of mobile, laptop, and tablet users. Emerging economies in the Asia Pacific region are expected to grow at the highest CAGR owing to rising awareness regarding the Hematological Malignanciess and continuous improvement in the healthcare infrastructure.

This report segments global Hematological Malignancies market on the basis of treatment, and regional market as follows:

Global Hematological Malignancies Market, by Treatment: Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy, and Surgical Treatment
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region.

This report identifies all the major companies operating in the global Hematological Malignancies market. Some of the major companies’ profiles in detail are as follows:

Takeda Pharmaceutical Company Limited
Celgene Corporation
AbbVie, Inc.

Pfizer, Inc.

Abbott Laboratories
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 2
1. Global Hematological Malignancies – Market Overview

2. Executive Summary

3. Global Hematological Malignancies Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Global Hematological Malignancies – Market Forces
4.1. Drivers
4.1.1. Rising Prevalence of Diseases
4.2. Restraints
4.2.1. High Cost Of The Diagnosis And Treatment
4.3. Opportunities
4.3.1. Extensive R&D Practices and Innovations
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Global Hematological Malignancies Market- By Treatment
5.1. Immunotherapy
5.2. Radiotherapy
5.3. Chemotherapy
5.4. Hormone Therapy
5.5. Surgical Treatment

6. Global Hematological Malignancies Market- By Geography
6.1. Europe
6.1.1. Germany
6.1.2. France
6.1.3. Italy
6.1.4. Spain
6.1.5. Russia
6.1.6. U.K.
6.1.7. Rest of Europe
6.2. Asia Pacific
6.2.1. China
6.2.2. India
6.2.3. Japan
6.2.4. South Korea
6.2.5. Rest of Asia-Pacific
6.3. North America
6.3.1. U.S.
6.3.2. Canada
6.3.3. Mexico
6.4. Rest of the World (RoW)
6.4.1. Brazil
6.4.2. Rest of RoW

7. Global Hematological Malignancies – Market Entropy
7.1. Expansion
7.2. Technological Developments
7.3. Merger & Acquisitions, and Joint Ventures
7.4. Supply- Contract

8. Company Profiles
8.1. Takeda Pharmaceutical Company Limited
8.1.1. Introduction
8.1.2. Financials
8.1.3. Key Insights
8.1.4. Key Strategy
8.1.5. Product Portfolio
8.1.6. SWOT Analysis
8.2. Celgene Corporation
8.2.1. Introduction
8.2.2. Financials
8.2.3. Key Insights
8.2.4. Key Strategy
8.2.5. Product Portfolio
8.2.6. SWOT Analysis
8.3. AbbVie, Inc.
8.3.1. Introduction
8.3.2. Financials
8.3.3. Key Insights
8.3.4. Key Strategy
8.3.5. Product Portfolio
8.3.6. SWOT Analysis
8.4. Pfizer, Inc.
8.4.1. Introduction
8.4.2. Financials
8.4.3. Key Insights
8.4.4. Key Strategy
8.4.5. Product Portfolio
8.4.6. SWOT Analysis
8.5. Abbott Laboratories
8.5.1. Introduction
8.5.2. Financials
8.5.3. Key Insights
8.5.4. Key Strategy
8.5.5. Product Portfolio
8.5.6. SWOT Analysis
8.6. GlaxoSmithKline Pharmaceutical Ltd.
8.6.1. Introduction
8.6.2. Financials
8.6.3. Key Insights
8.6.4. Key Strategy
8.6.5. Product Portfolio
8.6.6. SWOT Analysis
8.7. AstraZeneca
8.7.1. Introduction
8.7.2. Financials
8.7.3. Key Insights
8.7.4. Key Strategy
8.7.5. Product Portfolio
8.7.6. SWOT Analysis
8.8. Pharmacyclics
8.8.1. Introduction
8.8.2. Financials
8.8.3. Key Insights
8.8.4. Key Strategy
8.8.5. Product Portfolio
8.8.6. SWOT Analysis
8.9. Janssen Pharmaceutical Companies
8.9.1. Introduction
8.9.2. Financials
8.9.3. Key Insights
8.9.4. Key Strategy
8.9.5. Product Portfolio
8.9.6. SWOT Analysis
8.10. Novartis
8.10.1. Introduction
8.10.2. Financials
8.10.3. Key Insights
8.10.4. Key Strategy
8.10.5. Product Portfolio
8.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

9. Appendix
9.1. Abbreviations
9.2. Sources
9.3. Research Methodology
9.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 2